Default company panoramic image

Madam Therapeutics

We are an innovative biotech company developing a proprietary new class of antibiotics that are active against drug-resistant bacteria.

  • Stage Product In Development
  • Industry Biotechnology
  • Location 1078 Amsterdam, NH, The Netherlands
  • Currency EUR
  • Founded March 2011
  • Employees 2
  • Website

Company Summary

Our first product will improve the quality of life for 80-100 million atopic dermatitis patients worldwide. We develop it up to and including phase II clinical studies before licensing to a partner. The program management and business development are internal, all the other activities are outsourced. We are in pre-clinical development (financed), and are looking for financing for the clinical development which is anticipated to commence H2-2014.


  • Default avatar
    Remko van Leeuwen
    Chief Executive Officer

    Remko has extensive medical and regulatory experience in drug development. He is an experienced clinical trialist/epidemiologist with focus on infectious diseases with >20 years of experience in working in global clinical trials. He is coordinator of several international drug/vaccine development consortia. He has also build up commercial experience at a CRO, being responsible for clinical study BD and financing.

  • Default avatar
    Michel de Baar
    Chief Business Officer

    Michel has over 15 years experience in program management and business development and licensing in the international pharma/biotech industry. Having worked with any type of organization, from small biotech to large pharma, he has build up a vast network. Furthermore, Michel has shown creativity to successfully structure licensing, co-development and partnering deals with any type of company taking all parties' needs and wishes into account.


  • Default avatar
    Axon Lawyers & NautaDutilh Netherlands
    Default avatar
    de Nieuwenhuizen Groep

Previous Investors

  • Default avatar